<DOC>
	<DOCNO>NCT00079027</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , work different way stop growth tumor cell , either kill cell stop cell divide . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . It yet know whether doxorubicin effective without chemoembolization treat unresectable hepatocellular carcinoma ( liver cancer ) . PURPOSE : This randomized phase III trial study doxorubicin give infusion see well work compare doxorubicin give chemoembolization treat patient advanced liver cancer remove surgery .</brief_summary>
	<brief_title>Doxorubicin By Infusion Chemoembolization Treating Patients With Advanced Unresectable Hepatocellular Carcinoma ( Liver Cancer )</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient advance unresectable primary hepatocellular carcinoma treat intravenous doxorubicin hydrochloride vs doxorubicin hydrochloride chemoembolization . Secondary - Compare response rate patient treat regimen . - Compare time progression patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . - Compare health economic implication regimens patient . OUTLINE : This randomize , control , multicenter study . Patients stratify accord participate center , stage disease , alpha-fetoprotein level ( &lt; 500 ng/mL v ≥ 500 ng/mL ) . Patients randomize 1 2 treatment arm . - Arm I ( control arm ) : Patients receive doxorubicin hydrochloride IV 3-5 minute day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II ( chemoembolization arm ) : Patients undergo transarterial chemoembolization use DC Bead doxorubicin hydrochloride . Chemoembolization repeat every 8 week total 3 course absence disease progression unacceptable toxicity . Quality life assess baseline week 10 24 . Patients follow 4 week every 12 week thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 280 patient ( 140 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma ( HCC ) Advanced , unresectable disease No clinically significant ascites No modified ChildPugh class C liver disease No main portal vein occlusion/involvement No extrahepatic tumor kind PATIENT CHARACTERISTICS : Age 18 ( 16 patient reside Scotland ) Performance status ECOG 02 Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.5 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 5.0 mg/dL Transaminases &lt; 2.5 time upper limit normal ( ULN ) INR &lt; 1.5 Renal Creatinine &lt; 2 time ULN Cardiovascular No New York Heart Association class III IV cardiac disease No acute angina No significant peripheral vascular disease No thrombosis main portal vein LVEF ≥ 50 % Other Not pregnant nursing Fertile patient must use effective contraception No concurrent serious medical condition No serious infection No psychological , familial , sociological , geographical factor would preclude study compliance No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy advance unresectable HCC Chemotherapy No prior systemic regional chemotherapy No prior chemotherapy advanced unresectable HCC No concurrent anticancer chemotherapy Endocrine therapy No prior hormonal therapy advance unresectable HCC Radiotherapy No prior radiotherapy advanced unresectable HCC No concurrent anticancer radiotherapy Surgery More 7 day since prior major surgery More 3 day since prior laparoscopy Other More 4 week since prior investigational agent More 6 week since prior ablative therapy must radiological evidence progression ablate site site disease No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>